Articles On Dimerix (ASX:DXB)

After eight months of soul-searching, Argenica says it has a viable path to approval with stroke drug candidate ARG-007 Company working toward phase IIb study, enrolling the most responsive stroke patient cohort For reasons not fully unde...

The S&P/ASX 200 rose 2.18% as global equities rebounded despite ongoing Middle East tensions Tech sector rises more than 13% in April to recover some losses, while healthcare falls 8.67% Adisyn surges 241% after key breakthrough, licen...

Phase III trials are a major catalyst for healthcare companies, mark final proving ground before potential regulatory approval and commercialisation Success can make or break a company with several ASX healthcare names now in the high-stak...

 Syntara is getting its myelofibrosis program back on track after last year’s setback All the latest news on the quarterly reporting fiesta Dimerix’s trial tweak is a case of trading off time versus risk   The developer of a drug for the...

Six straight losses for ASX after another soft finish Energy stands alone as oil rises… everything else struggles Utilities smashed, defensives lag as rate nerves creep back in   The S&P/ASX 200’s losing streak continues. That’s six d...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Key Highlights: An external statistical blinded review of ACTION3 data has achieved...

Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential Pitt Street says Dimerix has the key building blocks needed to commercialise DMX-200 in FSGS Euroz Hartleys says full FDA approva...

A gaggle of drug developers is due to disclose company-making clinical study results this year While late-stage clinical trial victory does not confer commercial success, the results tend to be ‘do or die’ In the main, share valuations don...

Telix shares surge up to 9% after this morning’s surprise deal with Regeneron Relating to therapies not yet being developed by Telix, the compact includes a US$40 million upfront payment Oh baby! Genesis returns with improved Monash IVF o...

Morgans healthcare analyst Iain Wilkie highlights seven ASX companies with upcoming catalysts  Dimerix moving into major catalyst window as investors look for further updates from Phase III trial of DMX-200 in FSGS Cynata has results of tw...

ASX health sector falls 1.85% for the past five days while broader market down  Racura Oncology soars as third and final patient dosed in CPACS Phase I trial  Telix submits new drug application to US FDA for brain cancer imaging agent TLX1...

The step from ‘science project’ to commercial asset in the ASX-listed biotechnology landscape is defined by a handful of key milestones, and none is more important than a Phase Three interim analysis, where the most dramatic value re-rating...

Dimerix to conduct blinded review of ACTION3 data later this month to confirm statistical assumptions for primary endpoint Aims to provide further confidence that, statistically, the trial powered to demonstrate treatment effect for primar...

ASX reverses week’s gains, falling 1.31% Oil surges more than 9%, returning to near US$100/barrel Energy makes lonely gains as market otherwise retreats   ASX resets two days of gains The S&P/ASX 200 has reset to Monday’s levels, unwi...

Dimerix’s ACTION3 study DMX-200 in focal segmental glomerulosclerosis doses final adult patient with 333 patients recruited Adult recruitment closed above the original 286-patient target with paediatric recruitment continuing as a separate...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

Rare diseases have become an increasingly attractive target for pharmaceutical companies  Canaccord’s Dr Shane Storey says there are strong incentives for companies to develop therapies for rare diseases Various ASX companies are focusing...

Highlights Australian biotechnology companies reported regulatory and clinical updates. Trial modifications and site openings shaped sector activity. All Ordinaries classification reflects structured market participation....

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin An additional news report on the recommendation, valuation, forecast and opinion cha...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

Stockhead’s Tylah Tully previews the 2026 ahead for  Dimerix (ASX:DXB) and recaps the goals the company achieved throughout 2025. Tune in to hear all the details.   This video was developed in collaboration with Dimerix, a Stockhead adverti...

Will Actinogen’s Xanamia trial prove a bigger hit than ABBA, or is it the company’s Waterloo? Upbeat Mach 7 licks its wounds after contract loss Neurizon and Heramed go to the well Alzheimer’s disease drug hopeful Actinogen Medical (ASX:A...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to the soaring highlights and cratering lowlights.   As usual we adopt the user-friendly A to Z format. If only drug, device and diagnos...

In a tight race, drug developer Nyrada so far is this year’s star performer with almost an eightfold gain Diagnostic house Lumos and imagers Artrya and 4D Medical also have run a good race, with their US plans unfolding to script Nyrada ch...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

ASX green across the board, up 0.91% Materials and energy lead gains Broad-based market rally with 142 stocks higher   Gold hits new all-time high The ASX 200 started the shorter pre-Christmas week with a bang, up 0.91% or 78.5 points. Go...

Host Tylah Tully sits down with biopharmaceutical Dimerix (ASX:DXB) CEO and managing director Dr Nina Webster to explore how biotech companies can align R&D with commercial strategy from day one. Dr Webster explains why starting with th...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Recruitment successfully completed in Dimerix’ ACTION3 Phase 3 clinical trial[1], w...

Recruitment complete in Dimerix’s ACTION3 phase III clinical trial of DMX-200 in rare kidney disease focal segmental glomerulosclerosis The global trial has recruited and dosed its target 286th adult patient with 69 patients already comple...

In a pre-Christmas rush, biotechs report a flurry of clinical activity Radiopharm shares surge up to 22% on strong brain-imaging results Morgans says Sigma Health and EBOS Group shares are just the prescription for the Christmas hamper  ...

Highlights Major Australian leaders show sustained downward price pressure Select growth and technology names face renewed selling pressure A handful of emerging resources and healthcare stocks still trend higher Austr...

With over half the world’s population, the Asia-Pacific region looms as a major growth opportunity for Dimerix Shift in development pathway for pharmaceuticals seeking approval in major Asia-Pacific markets increases opportunity Dimerix ha...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX health sector fell 1.8% for the week, while broader market dropped 3.86% in the same period  FDA confirms Animal Rule and PRV potential for Island Pharmaceutical’s Galidesivir in Marburg Clever Culture identifies more than $45 million...

ASX climbs +0.23% before falling -0.25% Losses in banks, utilities, info tech undercut recovery Energy, materials, real estate mount resistance Markets wobble into red The ASX 200 obviously hasn’t quite recovered from the beating it took...

Seventh Independent Data Monitoring Committee review completed for Dimerix’s ACTION3 phase III study Committee recommends study of DMX-200 in kidney disease Focal Segmental Glomerulosclerosis continues unchanged Next scheduled meeting of I...

Strong clinical data can help biotechs secure lucrative licensing and partnership deals  Dimerix has four licensing deals for lead drug DMX-200 in rare kidney disease Platinum’s Global Health Sciences Fund manager Dr Bianca Ogden notes se...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

ASX retreats from session highs of +0.63pc to climb +0.30pc Gold and silver stocks recover from recent sell down NAB losses undercut broader gains   Precious metals get a polish The ASX 200 has bounced after closing at a three-week low ye...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

CSL watchers slash their valuations, yet retain faith in an eventual turnaround Medibank Private investors should Live Better now Dimerix’s trial plans are on track   CSL (ASX:CSL) analysts haven’t exactly given up on the stock following...

ASX closes at new high of 9094 points, up 0.7pc Broad momentum across sectors with 10 of 11 higher US-Australian critical mineral deals fuel more resource stock gains   ASX roars to new highs on US-Australia rare earths deal The ASX 200 s...

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode, Nadine chats with Dimerix  Managing Director Nina Webster.     Dimerix is a clinical-stage biopharmaceuti...

ASX 200 closes 0.13% lower on Friday, despite eight of 11 sectors higher  Tech sector leads gains while resource stocks weigh heavily Trigg Minerals continues to progress its proposed US Nasdaq listing    The ASX 200 ended the week lower...

ASX health sector moved up 1.30% for the week, while broader market inched up 0.12% This week: PainChek’s groundbreaking digital app scored coveted FDA De Novo clearance; The FDA lifted a clinical hold on Neurizon’s lead drug candidate for...

Stockhead’s Fraser Palamara catches up with Nina Webster, Managing Director at Dimerix (ASX:DXB), where she talks through the final data that has been released from the company’s recent collaboration with PARASOL, reinforcing the endpoints...

Final data analysis by the PARASOL collaboration with Dimerix generally consistent with broader analysis of FSGS patient data in 2024 Potential relationship was observed between proteinuria at 12 months and subsequent risk of kidney failur...

ASX down 9 points as AI jitters and profit taking set in Healthcare, materials sectors limit losses with some solid gains PainChek and Neurotech grab headlines with FDA wins; Dimerix also gains on strong news Glencore Mt Isa smelter bailed...